Rhythm Pharmaceuticals, Inc. (FRA:1RV)

Market Cap	6.52B +81.4%
Revenue (ttm)	188.35M +58.7%
Net Income	-180.26M
EPS	-2.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	93.50
Previous Close	93.50
Day's Range	93.50 - 93.50
52-Week Range	52.00 - 99.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 414
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1RV

Financial Performance

In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error